CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
PRT064445/Apixaban +2 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01758432
NCT01758432Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers

Portola Pharmaceuticals·interventional·Posted Jan 1, 2013·Updated Aug 7, 2023

In Brief

A Phase 2 clinical trial evaluating PRT064445/Apixaban, Placebo/Apixaban, and 1 other intervention for Healthy Volunteers. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 1, 2013
Enrollment StartDec 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.5 years ago

Interventions

PRT064445/Apixabancombination

Placebo/Apixabancombination

Placebodrug